Jan 17, 2017 Letter to OWCP Shareholders http://finance.yahoo.com/news/owc-pharmaceutical-research-corp-issues-121500795.html OWCP's Action Items for 2017: During the second quarter of 2017 OWCP intends to initiate its U.S marketing program for its Psoriasis Topical Cream. At the same time, we intend to begin investigating the applicability of topical cream for other skin conditions and disorders.
OWCP intends to proceed with the advancement of our cannabis-based treatment for multiple myeloma, with the objective of proceeding with additional studies.
OWCP intends to evaluate the launch of one or more studies to determine the applicability of cannabinoid-based pharmaceuticals for other medical conditions and disorders, such as fibromyalgia and migraines.
Why am I so confident in OWCP? Here are 16 reasons from 2016!
- #16.Though it didn’t take place in 2016, it’s still huge. TEVA, a 115 year old pharmaceutical company with over $20B in revenue, made an offer to purchase OWCP’s patents! This leads me to believe there will be future offers as OWCP continues to
advance their research and get closer to shipping products worldwide!
OWCP: Market Potential of Upcoming Products
So, as I’ve pointed out – a handful of Cannabis/Marijuana companies with billions of Outstanding Shares, generating little or no revenue, posting annual losses, and who are still being financed with (Toxic) Convertible Notes achieving a Market Value of $115M all the way to $424M (for a company with $2.1M revenue, but still with billions of shares)… Why on God’s green Earth would OWCP not climb to dollars per share? (Note: $2/share is a $280M Market Value)
OWCP: Annual Letter to Shareholders
I’ve pointed out in our Year End Recap that Jeffrey Friedland is a huge asset. Quite frankly, I’m a fan of Mr. Friedland. He’s all over the Medical Marijuana industry events.
Mr. Friedland has been featured or quoted in numerous publications including the Wall Street Journal, Reuters, the New York Times, Bloomberg Television, USA Today, VersloZinios (Lithuania), Vercernji (Croatia), International Business Times, the South China Morning Post, the Guam Daily Post, the Forward, the Jewish Week, Quartz, the Jakarta Globe, Israel Daily Television, BreitBart, NBC.com and Forbe
OWCP: Recent TEVA Pharma Buyouts
Here’s how I came up with my $500M valuation (which, is quite possibly very conservative):
- OWCP has NO TOXIC Debt
That was announced in an 8-K back in October. (This isn’t some OTC Pink Sheet operation.) They have real investors. That same October 8-K talks about a $300,000 non-interest bearing loan. They have royalty-based distribution deals with MedMar and Michepro, because the distributor obviously has confidence too.
I would recommend to my friends, do some DD and look up what OWCP may be working on with their Patent for Nasal Spray
Cannabis Nasal Spray can stop seizures in their tracks,
these sprays can also be used for Parkinson Disease
and pain from Cancers
Also Cannabis Nasal Sprays can help with Brain Cancer
(for people who have trouble swallowing these sprays really help)
Cannabis nasal spray stop grand mal seizure in children
BIG MONEY !
FULL ARTICLE READ THIS!
OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of medical conditions and disorders, today announced that
Ms. Miri Sani has accepted nomination to the Company's Advisory Board.
OWCP: The Blessing of Some Investors “Not Getting It”
If you’re able to buy under $1.50/share — I really think that’s a “blessing” because I really, really think it’s obvious the shares will be worth $4.00 – $5.00 by end of Quarter 2. After all, the Sublingual Tablet could very well have some updates/progress and expected launch dates announced sometime in Quarter 2 as well.
OWCP positions itself to sell in Germany, the world's 3rd largest medical market. Miri Sani, Vice Chairwoman (Israel)
"Israel is one of the most innovative countries in the world with regard to life sciences. Main areas are medical devices, biotechnology and health-related software. Some Israeli firms are world-leaders (TEVA, Given Imaging) in specific sub-segments of the life-science industry. However, most life-science-based companies are SMEs. These SMEs have difficulties in getting access to markets. The Israeli domestic market is small. The market entry into the US is expensive and risky due to high regulatory standards. Israeli firms tend to underestimate growth opportunities in continental Europe. Even though Germany has the third largest market for medical devices in the world, this market is often not high on the priority list of Israeli SMEs. The main hurdles are a general lack of information about Germany as a business location for life science firms and the difficulties in understanding the specifics of the German health care system. There is a variety of European, Federal, State and local incentive and support programs available for R&D in Germany for foreign and domestic firms alike, but the evaluation of these programs is time-consuming and can be discouraging for Israeli SMEs."
Video, Donald Trump Wants To Legalize Marijuana
President-elect Trump has made it clear that he supports medical marijuana.
6 Reasons Why Marijuana Wins No Matter Who Becomes Attorney General - See more at:
Feb 16, 2017 Video, Cannabis Caucus Federal and State level
Dun & Bradstreet report on Teva and their interest in OWC's patents.
READ, FEB 16, 2017 OWCP being ADDED TO Cannabis ETF What it Means.
"This is surprisingly great news and all out of the blue!"
**UPDATED** OWCP Corp Presentation PDF
OWCP KNOW WHAT YOU OWN !!
At minute 4;30 you will hear the efficacy study to be completed March 20, 2017 for the Psoriasis Cream ! Market readiness 2nd Quarter 2017
OWCP European Patent Register Links and Info
NOVEL CANNABINOID COMBINATION THERAPIES FOR MULTIPLE MYELOMA (MM) [/b
."Shareholders Meeting in Reno November 2017"
Staying at Circus Circus, Exact Dates and times TBA.
If you're interested in attending please send an email to Pussim
Please include your ihub handle and your real name along with contact information.